Rafael Holdings (RFL) Revenue (2017 - 2026)
Rafael Holdings' (RFL) quarterly Revenue came in at $179000.0 in Q2 2026, down 50.55% year-over-year from $362000.0 in Q2 2025, and down 15.17% quarter-over-quarter from $211000.0 in Q1 2026.
Analysis
Rafael Holdings (RFL) Revenue (2017 - 2026) Analysis & Trends
Rafael Holdings (RFL) has reported Revenue for 10 consecutive years, with $179000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Revenue fell 50.55% year-over-year to $179000.0 in Q2 2026; TTM through Apr 2026 was $980000.0, a 33.88% increase from a year earlier, with the FY2025 full-year figure at $917000.0, up 43.96% from the prior year.
- Revenue was $179000.0 for Q2 2026 at Rafael Holdings, down from $211000.0 in the prior quarter.
- Over five years, Revenue peaked at $362000.0 in Q2 2025 and troughed at $68000.0 in Q3 2023.
- A 5-year average of $149000.0 and a median of $76500.0 in 2022 frame the typical range for Revenue.
- Across the five-year window, Revenue tumbled 92.32% in 2022 and jumped 373.24% in 2024, its largest moves.
- Over 5 years, Revenue stood at $70000.0 in 2022, then decreased by 2.86% to $68000.0 in 2023, then surged by 88.24% to $128000.0 in 2024, then soared by 87.5% to $240000.0 in 2025, then fell by 25.42% to $179000.0 in 2026.
- The last three Revenue figures came in at $179000.0 (Q2 2026), $211000.0 (Q1 2026), and $240000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | 179,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 179,000.00 |
| Jan 31, 2026 | 211,000.00 |
| Oct 31, 2025 | 240,000.00 |
| Jul 31, 2025 | 350,000.00 |
| Apr 30, 2025 | 362,000.00 |
| Jan 31, 2025 | 77,000.00 |
| Oct 31, 2024 | 128,000.00 |
| Jul 31, 2024 | 165,000.00 |
| Apr 30, 2024 | 336,000.00 |
| Jan 31, 2024 | 68,000.00 |
| Oct 31, 2023 | 68,000.00 |
| Jul 31, 2023 | 68,000.00 |
| Apr 30, 2023 | 71,000.00 |
| Jan 31, 2023 | 70,000.00 |
| Oct 31, 2022 | 70,000.00 |
| Jul 31, 2022 | 69,000.00 |
| Apr 30, 2022 | 76,000.00 |
| Jan 31, 2022 | 74,000.00 |
| Oct 31, 2021 | 191,000.00 |
| Jul 31, 2021 | -2.20 Mn |